In silico assessment of coriander leaf extract active compound to resensitize oxaliplatin resistance in colorectal cancer mediated by ABCG2 and UPF1 proteins
DOI:
https://doi.org/10.55779/nsb16412125Keywords:
colorectal cancer, coriander leaf, molecular docking, oxaliplatin, rutinAbstract
Colorectal cancer is, and continues to be, one of the most important global health burdens due to its notorious high mortality rate and continuous resilience to traditional modes of treatment, specifically chemotherapeutic agents such as oxaliplatin. The resistance is mediated through specified genes highly involved in survival and resistant mechanisms in cancerous cells, like ABCG2 and UPF1 genes. Given the challenge, this study focuses on the coriander leaf extract as a new strategy for overcoming oxaliplatin resistance in colorectal cancer. In the present study, the authors examined the anticancer activities of the extracts from coriander leaves, which exerted inhibitory activity toward ABCG2 and UPF1 proteins believed to be involved in chemoresistance. Molecular docking analysis was done by PyRx software to evaluate the binding properties of the target genes with the 31 compounds in coriander leaf extract to find the best compound that may give an efficient way of overcoming resistance against oxaliplatin. Out of all the compounds screened, rutin came out to be the potential candidate. The binding affinities were highly impressive, about -8.4 kcal/mol for UPF1 and -7.8 kcal/mol for ABCG2. These values are especially important because they exceed the conventional affinity of known chemotherapy inhibitors, such as Ko143 and actinomycin D, which served as positive controls in this study. The higher binding affinity of rutin indicates that it may potentiate chemotherapy by specifically targeting ABCG2 and UPF1 in colorectal cancer cells. This strategic approach could limit the resistance to oxaliplatin and increase the treatment success rate in colorectal cancer patients. The observations of this work open up new perspectives in the study of natural products as adjuvants or alternatives to traditional chemotherapy that, in the future, could give rise to more efficient and less toxic strategies against colorectal cancer.
Metrics
References
Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ, Schroeder M (2021). PLIP 2021: Expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Research 49(W1):W530-W534. https://doi.org/10.1093/nar/gkab294
Alcindor T, Beauger N (2021). Oxaliplatin: A review in the era of molecularly targeted therapy. Current Oncology 18(1):18-25. https://doi.org:/10.3747/co.v18i1.708
Devanabanda B, Kasi A (2022). Oxaliplatin. PubMed; StatPearls Publishing.
Dottorini L, Petrell, F, Ghidini A, Rea CG, Borgonovo K, Dognin G, … Luciani A (2023). Oxaliplatin in adjuvant colorectal cancer: is there a role in older patients? In Journal of Clinical Oncology 41(18):3300-3303). https://doi.org/10.1200/JCO.23.00354
Feng Y, Jin H, Guo K, Wasan HS, Ruan S, Chen C (2021). Causes of death after colorectal cancer diagnosis: A population-based study. Frontiers in Oncology 11. https://doi.org/10.3389/fonc.2021.647179
Guijarro LG, Sanmartin-Salinas P, Perez-Cuevas E, Toledo-Lobo MV, Montserrat , Zoullas S, … Ortega MA (2021). Actinomycin D arrests the cell cycle of hepatocellular carcinoma cell lines and induces p53-dependent cell death. A study of the molecular mechanism involved in the protective effect of IRS-4. Pharmaceuticals 14(9). https://doi.org/10.3390/ph14090845
Hsu H, Chen M, Baskaran R, Lin Y, Day CH, Lin Y, … Huang C (2018). Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate er stress induced apoptosis. Journal of Cellular Physiology 233(7):5458-5467. https://doi.org/10.1002/jcp.26406
Huang H, Nakamura T, Yasuzawa T, Ueshima S (2020). Effects of Coriandrum sativum on migration and invasion abilities of cancer cells. Journal of Nutritional Science and Vitaminology 66(5):468-477. https://doi.org/10.3177/jnsv.66.468
Huang XM, Yang, ZJ, Xie Q, Zhang, ZK, Zhang H, Ma JY (2019). Natural products for treating colorectal cancer: A mechanistic review. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 117. https://doi.org/10.1016/J.BIOPHA.2019.109142
Jarmoskaite I, Alsadhan I, Vaidyanathan PP, Herschlag, D (2020). How to measure and evaluate binding affinities. Elife 9:1-34. https://doi.org/10.7554/ELIFE.57264
Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ, Watanabe T (2015). Colorectal cancer. Nature Reviews Disease Primers 1(15065). https://doi.org/10.1038/nrdp.2015.65
Lyu C, Wang L, Stadlbauer B, Buchner A, Pohla H (2022). A pan-cancer landscape of ABCG2 across human cancers: Friend or foe?. International Journal of Molecular Sciences 23(24). https://doi.org/10.1038/nrdp.2015.65
Martin HI, Agnihotri V, Yennamalli RM, Sarkar A (2023). A beginner’s guide to measuring binding affinity during biomolecular interactions. In: Basic Biotechniques for Bioprocess and Bioentrepreneurship. Academic Press. Pp 259-270. https://doi.org/10.1016/B978-0-12-816109-8.00017-9
Murakami K, Umemura N, Adachi M, Motoki M, Ohkoshi E (2022). ABCG2 CD44 and SOX9 are increased with the acquisition of drug resistance and involved in cancer stem cell activities in head and neck squamous cell carcinoma cells. Experimental and Therapeutic Medicine 24(6):1-9. https://doi.org/10.3892/etm.2022.11658
Nie S, Huang Y, Shi M, Qian X, Li H, Peng C, Kong B, Zou X, Shen S (2018). Protective role of ABCG2 against oxidative stress in colorectal cancer and its potential underlying mechanism. Oncology Reports 40(4). https://doi.org/10.3892/or.2018.6594
Rea PA (2016). Plant atp-binding cassette transporters. Annual Review of Plant Biology 58(1):347-375. https://doi.org/10.1146/annurev.arplant.57.032905.105406
Rubani M, Parikesit AA (2024). Molecular simulation of coffee beans’ natural products as lead compounds for stroke remedy. Engineering Headway 6:145-155. https://www.scientific.net/Paper/Preview/601490
Sałagacka-Kubiak A, Zawada D, Saed L, Korderk R, Jelen A, Balcerczak E (2023). ABCG2 gene and ABCG2 protein expression in colorectal cancer—In Silico and wet analysis. International Journal of Molecular Sciences 24(13). https://doi.org/10.3390/ijms241310539
Sun W, Ge Y, Cui J, Yu Y, Liu B (2021). Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2. Molecular Therapy - Oncolytics 21:87-97. https://doi.org/10.1016/j.omto.2021.03.010
Tang EL, Rajarajeswaran J, Fung SY, Kanthimathi MS (2013). Antioxidant activity of Coriandrum sativum and protection against DNA damage and cancer cell migration. BMC complementary and Alternative Medicine 13:347. https://doi.org/10.1186/1472-6882-13-347
Victoria SA, Pramanda IT, Parikesit AA (2023). In silico study of alkaloid compounds with computational approach for selection of drug leads for COVID-19. Coronaviruses 4(3). https://doi.org/10.2174/2666796704666230823164137
Weidner LD, Zonghbi SS, Lu S, Sukla S, Ambudkar SV, Pike VW, Mulder J, Gottesman MM, Innis RB, Hall MD (2015). The inhibitor Ko143 is not specific for ABCG2. Journal of Pharmacology and Experimental Therapeutics 354(3):384-393. https://doi.org/10.1124/jpet.115.225482
Zanardelli M, Micheli L, Nicolai R, Failli P, Ghelardini C, Mannelli LDC (2015). Different apoptotic pathways activated by oxaliplatin in primary astrocytes vs. colorectal cancer cells. International Journal of Molecular Sciences 16(12):5386-5399. https://doi.org/10.3390/ijms16035386
Zhang C, Xu C, Gao X, Yao Q (2022). Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics 12(5):2115-2132. https://doi.org/10.7150/thno.69424
Zhu C, Zhang L, Zhao S, Dai W, Xu Y, Zhang Y, Zheng H, Sheng Q, Xu Y (2021). UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer. Cell Death Disease 12(519). https://doi.org/10.1038/s41419-021-03798-2

Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sun JESSICA, Sandra B. FILEMON, Sharron SANTOSA, Stephani C. MAHARANI, Arli A. PARIKESIT

This work is licensed under a Creative Commons Attribution 4.0 International License.
Papers published in Notulae Scientia Biologicae are Open-Access, distributed under the terms and conditions of the Creative Commons Attribution License.
© Articles by the authors; licensee SMTCT, Cluj-Napoca, Romania. The journal allows the author(s) to hold the copyright/to retain publishing rights without restriction.
License:
Open Access Journal - the journal offers free, immediate, and unrestricted access to peer-reviewed research and scholarly work, due SMTCT supports to increase the visibility, accessibility and reputation of the researchers, regardless of geography and their budgets. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.